Is there a pressing need for improving prognostication strategies in therapy-related myelodysplastic syndromes?

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1

    Zeidan AM, Al Ali N, Barnard J, Padron E, Lancet JE, Sekeres MA et al. Comparison of clinical outcomes and prognostic utility of risk stratification tools in patients with therapy-related vs de novo myelodysplastic syndromes: a report on behalf of the MDS Clinical Research Consortium. Leukemia 2017; 31: 1391–1397.

  2. 2

    Brunning RD, Orazi A, Germing U, Le Beau MM, Porwitt A, Baumann J et al. Myelodysplastic syndromes. In: Swerdlow S, Campos E, Lee Harris N, Jaffe ES, Pileri SA, Stein H et al. (eds). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press, World Health Organization: Lyon, France, 2008, pp 87–107.

  3. 3

    Singh ZN, Huo D, Anastasi J, Smith SM, Karrison T, Le Beau MM et al. Therapy-related myelodysplastic syndrome: morphologic subclassification may not be clinically relevant. Am J Clin Pathol 2007; 127: 197–205.

  4. 4

    Ok CY, Hasserjian RP, Fox PS, Stingo F, Zuo Z, Young KH et al. Application of the international prognostic scoring system-revised in therapy-related myelodysplastic syndromes and oligoblastic acute myeloid leukemia. Leukemia 2014; 28: 185–189.

  5. 5

    Nardi V, Winkfield KM, Ok CY, Niemierko A, Kluk MJ, Attar EC et al. Acute myeloid leukemia and myelodysplastic syndromes after radiation therapy are similar to de novo disease and differ from other therapy-related myeloid neoplasms. J Clin Oncol 2012; 30: 2340–2347.

  6. 6

    Quintás-Cardama A, Daver N, Kim H, Dinardo C, Jabbour E, Kadia T et al. A prognostic model of therapy-related myelodysplastic syndrome for predicting survival and transformation to acute myeloid leukemia. Clin Lymphoma Myeloma Leuk 2014; 14: 401–410.

  7. 7

    Ok CY, Patel KP, Garcia-Manero G, Routbort MJ, Peng J, Tang G et al. TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases. J Hematol Oncol 2015; 8: 45.

  8. 8

    Bejar R, Papaemmanuil E, Haferlach T, Garcia-Manero G, Maciejewski JP, Sekeres M et al. TP53 mutation status divides MDS patients with complex karyotypes into distinct prognostic risk groups: analysis of combined datasets from the International Working Group for MDS-molecular prognostic committee. Blood 2014; 124: 532.

Download references

Author information

Correspondence to X Calvo.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Calvo, X., Florensa, L. & Arenillas, L. Is there a pressing need for improving prognostication strategies in therapy-related myelodysplastic syndromes?. Leukemia 31, 2538–2539 (2017) doi:10.1038/leu.2017.237

Download citation

Further reading